Drug Trial Radar · NCT04460651
PREPARE-IT. Prevention and Treatment of COVID19 With EPA in Subjects at Risk - Intervention Trial
Last checked: Nov 20, 2026Latest source record: Sep 17, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
4,093
Actual
Start
Aug 14, 2020
Primary completion
Aug 30, 2021
Study completion Aug 30, 2021
Sponsor
- Lead sponsor
- Estudios Clínicos Latino AméricaAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Amarin Pharma Inc.
- First posted
- Jul 7, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The PREPARE-IT investigator-initiated trial program is a simple, pragmatic, therapeutic strategy evaluating pure icosapent ethyl (IPE) at initially higher doses intended to reduce infection rates and subsequent morbidity and mortality among subjects at high risk of infection due to COVID-19 (prevention arm), and to reduce the hospitalization rate and complications in patients with a positive diagnosis of COVID-19 (treatment arm).
Conditions
- COVID19
Interventions
Icosapent ethyl (IPE)Drug
Participants in this arm will receive study medication IPE with the following dosage schedule: 8 g of IPE (4 capsules every 12 hours - morning and evening, with food) for the first three days followed by 4 g of IPE (2 capsules every 12 hours - morning and evening, with food) thereafter (days 4-28 for treatment arm and 4-60 for prevention arm)
PlaceboDrug
Participants in this arm will receive placebo with the following dosage schedule: 8 g of placebo (4 capsules every 12 hours - morning and evening, with food) for the first three days followed by 4 g of placebo (2 capsules every 12 hours - morning and evening, with food) thereafter (days 4-28 for treatment arm and 4-60 for prevention arm)
Primary outcomes
What the sponsor says the trial is designed to measure.
- (A) Prevention Arm: SARS-CoV-2 positivity assesed up to day 60.Time frame: 60 days
- (B) Treatment Arm: COVID 19 related hospitalization (indication for hospitalization per the blinded investigator or actual hospitalization) or death assessed up to 28 daysTime frame: 28 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Instituto de Investigaciones Clínicas - Rosario
Rosario, Santa Fe Province, Argentina
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.